Effects of boron neutron capture therapy using borocaptate sodium in combination with a tumor-selective vasoactive agent in mice.
Boron neutron capture therapy (BNCT) destroys tumor cells by means of alpha particles and recoil protons emitted by 10B(n, alpha)7Li reaction. For BNCT to be effective, the tumor/normal tissue concentration ratio of 10B must be larger than 1.0, because neutron distribution is not selective. We examined the combination of 10B-enriched borocaptate sodium (BSH) with flavone acetic acid (FAA) as a model compound which causes vascular collapse in squamous cell carcinoma in mice (SCCVII tumors) and would increase the tumor/normal tissue concentration ratio of 10B. FAA (200 mg/kg, i.p.) was injected, and 5 min later BSH (75 mg/kg, i.v.) was administered, followed 15 to 180 min later by irradiation with thermal neutrons. The 10B concentrations were measured by prompt gamma ray spectrometry. Without FAA, tumor 10B concentrations were less than or equal to normal tissue concentrations at all time intervals, except that the concentrations were 1.7- to 2.7-fold greater in tumor than muscle at 15 and 180 min after injection of BSH. With FAA, 10B concentrations 2.1- to 6.9-fold greater in tumor than in muscle were achieved at all intervals tested. For blood and skin, significant differential accumulations were found in tumors at 120 and 180 min. Tumor/liver ratios were less than 1 at all times. Cell survival was determined by in vivo/in vitro colony assay, and increasing radiosensitization correlated with increasing tumor 10B concentrations, whether or not they were achieved with FAA. Tumor control rates, determined at 180 days after BNCT, similarly appeared to depend only on 10B levels at the time of irradiation. Because 10B levels correlate with the radiation response of tissues, a therapeutic gain would be expected whenever the tumor levels exceed normal tissue levels, such as in tumors located in muscle irradiated at 15-180 min after FAA + BSH, or in those in skin irradiated at 120 and 180 min.
Ono
K
K
Radiation Oncology Research Laboratory, Kyoto University, Osaka.
Masunaga
S
S
Kinashi
Y
Y
Takagaki
M
M
Akaboshi
M
M
Suzuki
M
M
Baba
H
H
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001894:Borohydrides / Q000008:administration & dosage*; D001895:Boron / Q000493:pharmacokinetics; D016754:Boron Neutron Capture Therapy; D002294:Carcinoma, Squamous Cell / Q000378:metabolism / Q000628:therapy*; D002470:Cell Survival; D005419:Flavonoids / Q000008:administration & dosage*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009132:Muscles / Q000378:metabolism; D009368:Neoplasm Transplantation; D013438:Sulfhydryl Compounds / Q000008:administration & dosage*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D001894:Borohydrides; D005419:Flavonoids; D013438:Sulfhydryl Compounds; C014651:mercaptoundecahydrododecaborate; C049328:flavone acetic acid; D001895:Boron